IL218665D0 - Anti-cd20 antibody for use in treatment of b-cell lymphomas - Google Patents

Anti-cd20 antibody for use in treatment of b-cell lymphomas

Info

Publication number
IL218665D0
IL218665D0 IL218665A IL21866512A IL218665D0 IL 218665 D0 IL218665 D0 IL 218665D0 IL 218665 A IL218665 A IL 218665A IL 21866512 A IL21866512 A IL 21866512A IL 218665 D0 IL218665 D0 IL 218665D0
Authority
IL
Israel
Prior art keywords
anti
treatment
cell lymphomas
use
cd20 antibody
Prior art date
Application number
IL218665A
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US9618098P priority Critical
Priority to PCT/US1999/018120 priority patent/WO2000009160A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22256115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL218665(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of IL218665D0 publication Critical patent/IL218665D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against receptors, cell-surface antigens, cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against animal or human tumor cells or tumor cell determinants
    • A61K51/1069Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/001Processes for the treatment of water whereby the filtration technique is of importance
    • C02F1/003Processes for the treatment of water whereby the filtration technique is of importance using household-type filters for producing potable water, e.g. pitchers, bottles, faucet mounted devices
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2307/00Location of water treatment or water treatment device
    • C02F2307/02Location of water treatment or water treatment device as part of a bottle
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
IL218665A 1998-08-11 2012-03-15 Anti-cd20 antibody for use in treatment of b-cell lymphomas IL218665D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US9618098P true 1998-08-11 1998-08-11
PCT/US1999/018120 WO2000009160A1 (en) 1998-08-11 1999-08-11 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

Publications (1)

Publication Number Publication Date
IL218665D0 true IL218665D0 (en) 2012-05-31

Family

ID=22256115

Family Applications (4)

Application Number Title Priority Date Filing Date
IL14134999A IL141349D0 (en) 1998-08-11 1999-08-11 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 anti-body
IL141349A IL141349A (en) 1998-08-11 2001-02-09 Anti-cd20 antibody for use in treatment of b-cell lymphomas
IL207358A IL207358A (en) 1998-08-11 2010-08-02 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
IL218665A IL218665D0 (en) 1998-08-11 2012-03-15 Anti-cd20 antibody for use in treatment of b-cell lymphomas

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL14134999A IL141349D0 (en) 1998-08-11 1999-08-11 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 anti-body
IL141349A IL141349A (en) 1998-08-11 2001-02-09 Anti-cd20 antibody for use in treatment of b-cell lymphomas
IL207358A IL207358A (en) 1998-08-11 2010-08-02 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

Country Status (27)

Country Link
US (13) US6455043B1 (en)
EP (7) EP2990054A1 (en)
JP (9) JP2002522511A (en)
KR (4) KR101063278B1 (en)
CN (5) CN100531798C (en)
AT (1) AT414536T (en)
AU (3) AU767965C (en)
BR (1) BR9913645A (en)
CA (1) CA2340091C (en)
CY (2) CY1108906T1 (en)
CZ (1) CZ303898B6 (en)
DE (1) DE69939939D1 (en)
DK (2) DK1112084T4 (en)
EA (1) EA004107B1 (en)
ES (2) ES2388893T3 (en)
HK (3) HK1083444A1 (en)
HU (1) HU228180B1 (en)
IL (4) IL141349D0 (en)
MX (1) MXPA01001530A (en)
MY (1) MY136203A (en)
NO (2) NO332893B3 (en)
NZ (2) NZ573838A (en)
PL (1) PL195870B1 (en)
PT (2) PT1112084E (en)
TW (4) TWI355941B (en)
WO (1) WO2000009160A1 (en)
ZA (1) ZA200101157B (en)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
AT196606T (en) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutic Use of chimeric and labeled antibodies which are directed against an antigen of differentiation, the expression of lymphocyte to human b is limited, for the treatment of B-cell lymphoma
EP2990054A1 (en) * 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
AT454166T (en) * 1998-11-09 2010-01-15 Biogen Idec Inc Treatment of patients obtaining bone marrow transplantation or transplantation of peripheral blood temm cells with anti-cd20 antibodies
EP1616572B1 (en) 1998-11-09 2010-09-01 Biogen Idec Inc. Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia
AU3672800A (en) * 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
NZ516491A (en) * 1999-07-12 2004-11-26 Idec Pharmaceuticals Inc Blocking immune response to a foreign antigen using an antagonist which binds to CD20
AU2005211669C1 (en) * 1999-08-11 2017-09-21 F. Hoffmann-La Roche Ag Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
MXPA02001398A (en) * 1999-08-11 2002-08-12 Idec Pharma Corp Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies.
EP2264070A1 (en) * 1999-08-11 2010-12-22 Biogen-Idec Inc. Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody
AT511857T (en) * 2000-02-16 2011-06-15 Genentech Inc Anti-april monoclonal antibody and its use for the treatment of immune diseases or cancer
IL151906D0 (en) * 2000-03-24 2003-04-10 Chiron Corp Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
CN1981868A (en) * 2000-03-31 2007-06-20 拜奥根Idec公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
AT440618T (en) * 2000-06-22 2009-09-15 Univ Iowa Res Found Combination of cpg and antibodies to cd19, cd20, cd22 or cd40 for the prevention or treatment of cancer.
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
KR20040023565A (en) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1373321A2 (en) * 2001-01-29 2004-01-02 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
EP2359849A1 (en) * 2001-04-02 2011-08-24 Genentech, Inc. Combination therapy
WO2002102312A2 (en) * 2001-06-14 2002-12-27 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
BR0211614A (en) * 2001-08-03 2006-10-31 Genentech Inc tacis and br3 polypeptide and their uses
US7255858B2 (en) * 2001-08-10 2007-08-14 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AT482719T (en) 2002-02-21 2010-10-15 Univ Duke Treatment procedure using anti-cd22 antibodies
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
EP2377549A1 (en) * 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 for treating viral infections
NZ537781A (en) * 2002-07-25 2008-04-30 Genentech Inc Taci antibodies and uses thereof
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP2316856B1 (en) * 2002-10-17 2017-08-09 Genmab A/S Human monoclonal antibodies against CD20
MXPA05006306A (en) * 2002-12-13 2005-09-21 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent.
SE0203731D0 (en) * 2002-12-13 2002-12-13 Mitra Medical Technology Ab Reagent
CN1748143A (en) * 2002-12-16 2006-03-15 健泰科生物技术公司 Transgenic mice expressing human cd20 and/or cd16
ES2633311T3 (en) 2002-12-16 2017-09-20 Genentech, Inc. Immunoglobulin variants and uses thereof
CN101371924A (en) * 2003-04-09 2009-02-25 健泰科生物技术公司 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-ALPHA inhibitor
JP5416338B2 (en) * 2003-05-09 2014-02-12 デューク ユニバーシティ CD20-specific antibody and method of use thereof
AR044388A1 (en) * 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 binding molecules
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
AU2004256042A1 (en) * 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
DK1648507T3 (en) * 2003-07-24 2017-05-01 Innate Pharma Sa Procedures and compositions for increasing the effectiveness of therapeutic antibodies using compounds that potentate nk cells
US20060240005A1 (en) * 2003-07-24 2006-10-26 Universita Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
AU2004264601A1 (en) * 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti CD20 antibodies and uses therefor
BRPI0412629A (en) * 2003-08-29 2006-09-26 Genentech Inc Method of treating eye dysfunction in mammals
KR20060126449A (en) * 2003-09-23 2006-12-07 파브릴, 인크. Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
ES2428358T3 (en) * 2003-10-17 2013-11-07 Novo Nordisk A/S Combination therapy
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
CN104829719A (en) 2003-11-05 2015-08-12 罗氏格黎卡特股份公司 CD20 antibodies with increased FC receptor binding affinity and effector function
KR20090036154A (en) * 2003-12-19 2009-04-13 제넨테크, 인크. Detection of cd20 in therapy of autoimmune diseases
KR20060107555A (en) * 2003-12-19 2006-10-13 제넨테크, 인크. Detection of cd20 in transplant rejection
CA2550998A1 (en) * 2003-12-22 2005-07-14 Chiron Corporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
MXPA06011805A (en) * 2004-04-16 2006-12-15 Genentech Inc Method for augmenting b cell depletion.
WO2005115453A2 (en) * 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ZA200608982B (en) * 2004-05-05 2008-06-25 Genentech Inc Preventing autoimmune disease by using an anti-CD20 antibody
CN103127502A (en) 2004-05-20 2013-06-05 津莫吉尼蒂克斯公司 Methods of treating cancer using IL-21 and monoclonal antibody therapy
ZA200610158B (en) * 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
SV2006002131A (en) * 2004-06-04 2006-01-26 Genentech Inc Using an antibody to treat lupus
MX2007000327A (en) * 2004-07-09 2007-03-12 Schering Ag Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma.
BRPI0513100A (en) * 2004-07-22 2007-10-23 Genentech Inc methods of treating sjígren's syndrome and manufactured articles
CN101001873B (en) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Variant fc regions
EP1812060A2 (en) * 2004-10-05 2007-08-01 Genentech, Inc. Method for treating vasculitis
GB2420976B (en) * 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
CA2590163A1 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
KR20070094928A (en) 2005-01-21 2007-09-27 제넨테크, 인크. Fixed dosing of her antibodies
DOP2006000029A (en) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and use thereof. (Variants of an antibody and uses thereof)
AU2006214244A1 (en) * 2006-02-14 2006-08-24 Novartis Vaccines And Diagnostics Inc. Methods for treating lymphomas using a combination of a chemotherapeutic agent and IL-2 and optionally an anti-CD20 antibody
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
MX2007011064A (en) * 2005-03-23 2008-02-19 Genmab As Antibodies against cd38 for treatment of multiple myeloma.
AR053579A1 (en) * 2005-04-15 2007-05-09 Genentech Inc Treatment of inflammatory bowel disease (IBD)
EP2360181B1 (en) * 2005-04-18 2013-09-18 Novo Nordisk A/S IL-21 variants
ZA200708857B (en) * 2005-04-22 2009-01-28 Genentech Inc Method for treating dementia or alzheimer's disease with a CD30 antibody
CN101223448B (en) * 2005-05-20 2012-01-18 健泰科生物技术公司 Pretreatment of a biological sample from an autoimmune disease subject
KR20080047540A (en) 2005-07-25 2008-05-29 트루비온 파마슈티칼스, 인코포레이티드 Single dose use of cd20-specific binding molecules
SI2298815T1 (en) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2639242A3 (en) 2006-03-06 2013-10-16 MedImmune, Inc. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7727525B2 (en) * 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
CN105837690A (en) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 Single-chain multivalent binding proteins with effector function
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
WO2008049920A2 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
US8211420B2 (en) * 2006-12-21 2012-07-03 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
CA2680564C (en) * 2007-03-12 2018-05-01 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
WO2008132500A2 (en) * 2007-04-27 2008-11-06 Astrazeneca Ab Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
SI2631248T1 (en) 2007-06-15 2018-04-30 Medigene Ag Treatment of tumors using specific anti-L1 antibody
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CA2689064C (en) * 2007-06-25 2018-04-24 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
HUE037162T2 (en) 2007-07-09 2018-08-28 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
ES2527297T3 (en) 2007-07-31 2015-01-22 Regeneron Pharmaceuticals, Inc. Human antibodies for human CD20 and method to use them
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US20090169550A1 (en) * 2007-12-21 2009-07-02 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
CN102076715B (en) 2008-06-25 2018-06-19 艾斯巴技术-诺华有限责任公司 The dissolubility optimization of immunoconjugator
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX355650B (en) 2009-08-11 2018-04-26 Genentech Inc Production of proteins in glutamine-free cell culture media.
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche highly concentrated anti-CD20 antibody of pharmaceutical formulations. Use of the formulation. treatment method.
RU2573994C2 (en) 2010-02-10 2016-01-27 Иммьюноджен, Инк Anti-cd20 antibodies and thereof application
DE102010015276A1 (en) 2010-04-15 2011-10-20 A. Eberle Gmbh & Co. Kg Control / regulation of the secondary voltage of local power transformers through the use of line-commutated inverters
US9249226B2 (en) 2010-06-09 2016-02-02 Genmab A/S Antibodies against human CD38
EP2600895A1 (en) * 2010-08-03 2013-06-12 Hoffmann-La Roche AG Chronic lymphocytic leukemia (cll) biomarkers
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013543381A (en) 2010-10-01 2013-12-05 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Engineered nucleic acids and methods of use
US9605320B2 (en) 2011-01-13 2017-03-28 The Board Of Trustees Of The Leland Stanford Junior University Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US20140227277A1 (en) * 2011-08-16 2014-08-14 Morphosys Ag Combination therapy with an anti-CD19 antibody and a purine analog
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140234307A1 (en) 2011-09-27 2014-08-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
EP3492109A1 (en) 2011-10-03 2019-06-05 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (en) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Modified nucleosides, nucleotides and nucleic acid compositions
WO2013063186A2 (en) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-03-30 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc Modified polynucleotides for the production of membrane proteins
AR092612A1 (en) 2012-09-21 2015-04-29 Regeneron Pharma Anti-CD3 antibodies, bispecific binding molecules that bind antigen CD3 and CD20, and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
RU2550663C2 (en) * 2013-02-13 2015-05-10 Владимир Владимирович Савостьянов Method of hormonal and radiation preparation of patients with chronic lymphocytic leukaemia for following chemotherapy
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
KR20160098464A (en) 2013-12-17 2016-08-18 제넨테크, 인크. Anti-cd3 antibodies and methods of use
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
JP2018527882A (en) 2015-05-30 2018-09-27 モレキュラー テンプレーツ,インク.Molecular Templates, Inc. Deimmunized Shiga toxin A subunit scaffold and cell targeting molecule comprising the same
AU2016280102A1 (en) 2015-06-16 2017-12-07 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
GB201703876D0 (en) * 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
IL76591D0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
USRE38008E1 (en) * 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
IL85035D0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
JP3040121B2 (en) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド Method of treating tumor cells by inhibiting the function of the growth factor receptor
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
US5225535A (en) * 1988-12-15 1993-07-06 The Wistar Institute Lymphokine SAF and method of making
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
SE8903003D0 (en) 1989-09-12 1989-09-12 Astra Ab Novel medical use
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0556285A4 (en) 1990-11-05 1993-10-27 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
JP3105629B2 (en) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション Cell activity regulation conjugate of a member of a specific binding pair
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AT237638T (en) 1991-07-25 2003-05-15 Idec Pharma Corp Recombinant antibodies for human therapy
MX9204374A (en) * 1991-07-25 1993-03-01 Idec Pharma Corp recombinant antibody and method for its production.
ZA9300391B (en) * 1992-01-21 1993-10-06 Tamrock World Corp Battery changer on a mobile machine
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US6099846A (en) 1992-10-14 2000-08-08 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates
US5451518A (en) 1992-11-13 1995-09-19 Sloan-Kettering Institute For Cancer Research Purified human ceramide-activated protein kinase
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AT196606T (en) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutic Use of chimeric and labeled antibodies which are directed against an antigen of differentiation, the expression of lymphocyte to human b is limited, for the treatment of B-cell lymphoma
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5691135A (en) * 1993-01-26 1997-11-25 The Regents Of The University Of California Immunoglobulin superantigen binding to gp 120 from HIV
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5716791A (en) 1996-05-09 1998-02-10 Meridian Diagnostics, Inc. Immunoassay for H. pylori in fecal specimens
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP2990054A1 (en) 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
AU6047099A (en) * 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
AT454166T (en) 1998-11-09 2010-01-15 Biogen Idec Inc Treatment of patients obtaining bone marrow transplantation or transplantation of peripheral blood temm cells with anti-cd20 antibodies
EP1616572B1 (en) 1998-11-09 2010-09-01 Biogen Idec Inc. Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP2316856B1 (en) * 2002-10-17 2017-08-09 Genmab A/S Human monoclonal antibodies against CD20
ES2633311T3 (en) * 2002-12-16 2017-09-20 Genentech, Inc. Immunoglobulin variants and uses thereof

Also Published As

Publication number Publication date
NO20010699D0 (en) 2001-02-09
EP1112084A4 (en) 2002-10-16
CN1689645A (en) 2005-11-02
ES2317702T3 (en) 2009-04-16
EP2990054A1 (en) 2016-03-02
JP2017214435A (en) 2017-12-07
DK1112084T4 (en) 2012-07-23
ZA200101157B (en) 2002-07-10
CA2340091A1 (en) 2000-02-24
US20150183882A1 (en) 2015-07-02
PT1974747E (en) 2012-09-05
JP2010265318A (en) 2010-11-25
JP2017222727A (en) 2017-12-21
US20030206903A1 (en) 2003-11-06
EP1112084B2 (en) 2012-04-25
US8329172B2 (en) 2012-12-11
EP1112084B1 (en) 2008-11-19
JP6241794B2 (en) 2017-12-06
JP6253842B2 (en) 2017-12-27
AU767965C (en) 2005-04-21
KR101023367B1 (en) 2011-03-18
NO20010699L (en) 2001-04-10
US20170037140A1 (en) 2017-02-09
NO332893B3 (en) 2017-09-18
NZ573838A (en) 2011-01-28
JP2017128615A (en) 2017-07-27
AU2008207357B2 (en) 2011-07-14
AU767965B2 (en) 2003-11-27
CA2340091C (en) 2013-02-05
EP1974747B1 (en) 2012-06-27
AU2004200806A1 (en) 2004-03-25
MY136203A (en) 2008-08-29
KR101155957B1 (en) 2012-06-15
NZ528199A (en) 2005-06-24
CN1689644A (en) 2005-11-02
PL346046A1 (en) 2002-01-14
HU0103484A2 (en) 2002-01-28
IL207358A (en) 2017-09-28
BR9913645A (en) 2001-09-25
CN1320044A (en) 2001-10-31
PT1112084E (en) 2009-02-20
US9296821B2 (en) 2016-03-29
CN100531798C (en) 2009-08-26
HU228180B1 (en) 2013-01-28
PL195870B1 (en) 2007-11-30
EA200100224A1 (en) 2001-08-27
US20080038261A1 (en) 2008-02-14
TWI343817B (en) 2011-06-21
DK1112084T3 (en) 2009-03-16
CN101695574A (en) 2010-04-21
TWI355941B (en) 2012-01-11
NO20111217A1 (en) 2011-09-08
US20130273039A1 (en) 2013-10-17
HK1122511A1 (en) 2013-01-18
JP2002522511A (en) 2002-07-23
AU2008207357C1 (en) 2017-05-04
JP2015098486A (en) 2015-05-28
US20140056887A1 (en) 2014-02-27
IL141349A (en) 2012-06-28
IL141349D0 (en) 2002-03-10
US20120251534A1 (en) 2012-10-04
US10113000B2 (en) 2018-10-30
KR20090014243A (en) 2009-02-06
US20120258102A1 (en) 2012-10-11
IL207358D0 (en) 2011-08-01
DK1974747T3 (en) 2012-09-17
AT414536T (en) 2008-12-15
JP2019065023A (en) 2019-04-25
EP1112084A1 (en) 2001-07-04
NO332893B1 (en) 2013-01-28
TWI242444B (en) 2005-11-01
EP2263693A1 (en) 2010-12-22
EP1974747A1 (en) 2008-10-01
US20120251535A1 (en) 2012-10-04
JP2013227352A (en) 2013-11-07
US20120258101A1 (en) 2012-10-11
KR101063278B1 (en) 2011-09-07
EP2275136A1 (en) 2011-01-19
JP6226216B2 (en) 2017-11-08
US20030026804A1 (en) 2003-02-06
HK1083444A1 (en) 2009-05-08
CN100409898C (en) 2008-08-13
EP2260866A1 (en) 2010-12-15
TW200526248A (en) 2005-08-16
US20160333106A1 (en) 2016-11-17
CZ2001526A3 (en) 2002-11-13
AU5553199A (en) 2000-03-06
EA004107B1 (en) 2003-12-25
TWI322014B (en) 2010-03-21
ES2317702T5 (en) 2012-07-11
ES2388893T3 (en) 2012-10-19
CN1689646A (en) 2005-11-02
TW200846021A (en) 2008-12-01
CY1113600T1 (en) 2016-06-22
KR20110022097A (en) 2011-03-04
KR20090115895A (en) 2009-11-09
CY1108906T1 (en) 2014-07-02
WO2000009160A1 (en) 2000-02-24
JP2009173686A (en) 2009-08-06
US6455043B1 (en) 2002-09-24
EP1946775A2 (en) 2008-07-23
DE69939939D1 (en) 2009-01-02
HK1083449A1 (en) 2010-06-11
KR20080038453A (en) 2008-05-06
MXPA01001530A (en) 2002-04-24
AU2008207357A1 (en) 2008-09-04
TW201106974A (en) 2011-03-01
CZ303898B6 (en) 2013-06-19
EP1946775A3 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
DE69637511D1 (en) Use of ritonavir (abt-538) to improve the pharmacokinetics of drugs metabolised by cytochrome p450 as part of the treatment of AIDS
DK1390040T3 (en) Pharmaceutical preparation for use in hormone replacement therapy
DE60124302D1 (en) Thiazone derivatives for the treatment of ppar-life diseases
TWI238824B (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
DK1345895T3 (en) Hitherto diphenylazetid ions, methods for their preparation, drugs containing these compounds and their use in the treatment of lipid metabolism disorders
DE60135633D1 (en) Photodynamic therapy for the treatment of eye diseases
DE60120372D1 (en) Use of insulin for the treatment of cortical diseases
DE60023043T2 (en) (S, S) reboxetine for the treatment of incontinence
DE60037249D1 (en) Visually controlled instrument for the treatment of harnine incontinence in women
TW513412B (en) Aryl fused azapolycyclic compounds
DE69737510D1 (en) Use of an uncapped anti-cancer agent for producing preparation for the treatment of neoplasms by inhalation
TR200100278T2 (en) Oxazolo, thiazolo and selenazolo [4,5-c] -quinolin-4-amines and analogs thereof.
HU912266D0 (en) Process for the production of solid medical preparations with controlled portioning of the active agents for oral use
IE940809L (en) Ultrasonic contrast agents, process for their preparation¹and their use as diagnostic and therapeutic agents
EP1227836A4 (en) Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
MD1367C2 (en) Methods of B-cells lymphoma treatment, anti-CD20 antibodies, hybridoma
TW528755B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
BRPI0415858A (en) compounds of tocopherol-modified therapeutic drugs
EA200000723A1 (en) Derivatives 2- (purin-9-il) -tetrahydrofuran-3,4-diola
PT1017378E (en) Amida derivatives for the treatment of diseases mediated by cytokines
AU3949997A (en) Improved apparatus for ultrasonic therapeutic treatment
YU30004A (en) Use of flibanserin in the treatment of sexual disorders
MXPA05013564A (en) Fusion proteins.
PL218221B1 (en) Preparation containing human antibodies for the treatment of disorders associated with TNF-α
NZ511219A (en) Novel agents and methods for treatment and diagnosis of ocular disorders